Gilead Sciences Forecast: A Bullish Fundamental & Algorithmic Perspective
Summary
- Gilead Sciences is an American biotechnology
company with a distinguished product pipe line that, in recent years, has enjoyed high revenue, earnings-per-share, and net income growth. - In Q3 2014, Gilead grew year-over-year in a multitude of ways domestically and internationally; it also announced new research accomplishments, and maintained positive – if slightly slower – full-year guidance.
- While some analysts believe Gilead’s growth will come to an end because of technicals and inherent risk, fundamental analysis indicates that Gilead will keep thriving.
- I Know First’s algorithm predicts a bullish forecast for GILD in the 1-month and 3-month time frames.
About Gilead Sciences:
Gilead Sciences (NASDAQ: GILD) is an American biotechnology company that is involved in drug discovery, development, and commercialization. Founded in 1987 in Foster City, California, Gilead has since expanded to develop operations in the North and South Americas, Europe, and the Asia-Pacific region. Having made twelve or so acquisitions, minimally, since 1999, Gilead has made itself a biotech giant in recent years. At present, the company generates approximately $11.3 billion in revenue, boasts an innovative and diverse product pipeline focusing on HIV, hepatitis B, influenza, HCV, cardiovascular, and respiratory disorders, and has experienced highly impressive earnings growth. It has been labelled one of the fastest growing companies in America by Fortune, one of America’s top companies to work for by Forbes, and its acquisition of Pharmasset has been hailed as “one of the best pharma acquisitions ever” by the latter publication.
Despite the fact that Gilead is evidently doing quite well, therefore, and despite relatively strong Q3 results on the company’s part, certain analysts have put forward concerns surrounding Gilead’s ability to grow in the future. As such, an examination of Gilead-related fundamentals is in order!
